Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
Public ClinicalTrials.gov record NCT00381940. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease
Study identification
- NCT ID
- NCT00381940
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 26 participants
Conditions and interventions
Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- Adult Lymphocyte Predominant Hodgkin Lymphoma
- Adult Mixed Cellularity Hodgkin Lymphoma
- Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Adult Nodular Sclerosis Hodgkin Lymphoma
- Childhood Lymphocyte Depletion Hodgkin Lymphoma
- Childhood Lymphocyte Predominant Hodgkin Lymphoma
- Childhood Mixed Cellularity Hodgkin Lymphoma
- Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Childhood Nodular Sclerosis Hodgkin Lymphoma
- Recurrent Adult Hodgkin Lymphoma
- Recurrent/Refractory Childhood Hodgkin Lymphoma
- Stage I Adult Hodgkin Lymphoma
- Stage I Childhood Hodgkin Lymphoma
- Stage II Adult Hodgkin Lymphoma
- Stage II Childhood Hodgkin Lymphoma
- Stage III Adult Hodgkin Lymphoma
- Stage III Childhood Hodgkin Lymphoma
- Stage IV Adult Hodgkin Lymphoma
- Stage IV Childhood Hodgkin Lymphoma
Interventions
- bortezomib Drug
- filgrastim Biological
- ifosfamide Drug
- vinorelbine tartrate Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- Up to 29 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2006
- Primary completion
- May 31, 2008
- Completion
- Dec 30, 2016
- Last update posted
- Mar 23, 2021
2007 – 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Oncology Group | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00381940, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2021 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00381940 live on ClinicalTrials.gov.